MedTrace Logo

Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors

NCT06007274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-04-08

No results posted yet for this study

Summary

Recent guidelines suggest the use of troponin to detect immnune related cardiovascular advserse events in patients treated by immune checkpoint inhibitors for cancer.

However, there is no proof that patients on immune checkpoint inhibitors benefit from this active surveillance strategy. The suspicion of cardiovascular events may lead to the interruption of cancer therapies.

The TILT study aims at assessing: (i) the efficiency of troponin measurments in asymptomatic patients to prevent the further advent of major cardiovascular events; (ii) its safety in terms of cancer therapy completion.

Conditions

  • Cancer
  • Immune Checkpoint Inhibitor
  • Cardiovascular Biomarkers

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Institut Curie

    collaborator OTHER

  • Institut Mutualiste Montsouris

    lead OTHER

Principal Investigators

  • Mariana Mirabel, MD, PhD · Institut Mutualiste Montsouris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-04-01
Completion
2024-07-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06007274 on ClinicalTrials.gov